SEARCH

Current Edition

approval

Innovent receives IND approval to initiate Clinical Trials in China

Innovent’s IBI101, is the first OX40-targeted molecule to receive IND approval in China Innovent Biologics, a world-class China-based biopharmaceutical company that develops and intends to …

Continue Reading →